RxDoctor Payments Data

Danielle Carmitchel, APRN

Primary Care · Overland Park, KSNPI 1912678996

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 30.6% of the total.

$2,351in general payments, 2019–2025

Across 145 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$718
  • Novo Nordisk$425
  • Lilly USA, LLC$313
  • Bayer$175
  • AstraZeneca$153
  • Pfizer$88
  • plus $478 from 12 others

What the payments were for

  • Food & beverage$2,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,351 in reported general payments places this provider in the 85th percentile of 56 primary care providers in Kansas.

See all primary care providers in Kansas

Medicare billing

Part B allowed, 2024
$17,334
Medicare patients
153
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$20,726
Omeprazole36$759
Atorvastatin Calcium66$686
Gabapentin35$574
Albuterol Sulfate HfaAlbuterol Sulfate30$518
Fluticasone Propionate27$443
Bupropion XlBupropion Hcl15$418
Levothyroxine Sodium43$379
Ropinirole Hcl17$379
Doxycycline Hyclate24$296
Trazodone Hcl28$280
Lisinopril19$261
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$256
Rosuvastatin Calcium23$252
Escitalopram Oxalate12$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$425$20,72623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 primary care providers in Kansas.

Other primary care in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →